Peter Lange

Director/Miembro de la Junta en Technical University of Berlin .

80 años

Consumer Services

Health Technology

Perfil

Peter Lange is currently the Vice Chairman at the Technical University of Berlin and a Member-Supervisory Board at Vakzine Projekt Management GmbH since 2012.
He previously worked as a Lecturer at Eberhard Karls Universität Tübingen in 1994.
Dr. Lange has an undergraduate degree from the University of Gottingen and a doctorate degree from Eberhard Karls Universität Tübingen.

Cargos activos de Peter Lange

Empresas	Cargo	Inicio
Vakzine Projekt Management GmbH Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.	Corporate Officer/Principal	-
Technical University of Berlin	Director/Miembro de la Junta	16/11/2009

Todos los cargos activos de Peter Lange

Antiguos cargos conocidos de Peter Lange.

Empresas	Cargo	Fin
Eberhard Karls Universität Tübingen	Corporate Officer/Principal	01/01/1994

Ver el detalle de la experiencia de Peter Lange.

Formación de Peter Lange.

University of Gottingen	Undergraduate Degree
Eberhard Karls Universität Tübingen	Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Peter Lange.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
Vakzine Projekt Management GmbH Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.	Health Technology